Soleno Q1 net loss $43.8M; VYKAT XR launch: 268 patient forms, 131 prescribers

SOLENO THERAPEUTICS INC

2025-Q1 EPS reported -$0.95

VYKAT XR approved by FDA Mar 26; treatments started Apr 14; 268 patient start forms and 131 prescribers through May 6.
Q1 net loss $43.8M ($0.95 EPS) vs $21.4M ($0.59) a year ago; no revenue yet.
Cash and marketable securities $290.0M; operating cash use $32.8M in quarter.
R&D expense $13.5M; SG&A $29.3M, reflecting launch preparation costs.
MAA submission to EMA for DCCR on track for Q2 2025; contingent consideration liability $17.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.